Searched for
GV PRASAD INTERVIEW
Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman & MD GV PrasadDr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimi...- Friday OTT releases of the week (Feb 2 - Feb 8): Mana Shankara Vara Prasad Garu to The Raja Saab, new movies and shows on Netflix, JioHotstar, Prime VideoThis week’s OTT releases, streaming between February 2 and 8, bring a wide mix of content for viewers. From Telugu entertainers and interna...
- Big pharma mergers unlikely in near future: Dr Reddy's MD GV PrasadLarge mergers and acquisitions in the Indian pharmaceutical market are unlikely soon due to various uncertainties, says GV Prasad of Dr Red...
- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- ET Boardroom Dialogues 2023: What to expect at the two-day summit driving leadership action for a sustainable futureThe ET Boardroom Dialogues 2023, in partnership with Diageo India, will define the roadmap for accelerating the adoption of sustainable wat...
- Dr Reddy's Laboratories planning mergers and acquisitions to climb up ladderIndia contributed about a fifth or ₹4,196 crore of the company's overall sales of ₹21,439 crore in 2021-22, but domestic business has clock...
- Dr. Reddy's eyes Sputnik vaccine exports after domestic struggleLast month India resumed exports of COVID-19 vaccines for the first time since it banned shipments in April in a bid to focus on inoculatin...
- Dr Reddy’s, Merck’s Covid pill partner in India, sees a short-lived boomAnd this is despite Dr Reddy’s, one of India’s largest drugmakers, gearing to export Sputnik shots next year and expecting regulatory nod t...
- Dr. Reddy's open to making Pfizer COVID pill after Merck dealThe new drugs, which unlike vaccines can be used to treat patients once they contract coronavirus infection, are expected to be a huge mark...
- Capacity needed to manufacture Covid vaccines is unprecedented: DRL MDPrasad in an exclusive interview to ET said that three challenges with the Covid vaccine distribution are the sheer capacity expansion that...
- Can't say if the Teva deal is low-value, will take 2 months to get FTC clearance: GV Prasad, Dr Reddy’s LabsPrasad said that the company will bring in some interesting deals in proprietary product areas where the capital leverage is high.
- Can Indian generic makers find gold with a blockbuster Hepatitis C drug?Gilead has voluntarily licensed the drug to nearly a dozen Indian cos for a royalty fee in a model that has been lauded as one that balance...
- Ranbaxy saga has opened eyes of companies: GV Prasad, Dr Reddy’s LaboratoriesAs a company, we have always focussed heavily on improving quality systems, training, approach towards regulatory compliance.
- Falling standards of pharma companies is industry's big bane: GV Prasad, Chairman, Dr Reddy’s Lab"The pharmaceutical industry is facing pressure from regulators in the US because companies have allowed standards to decline"
- Dr Reddy’s Laboratories founder Anji Reddy passes awayAnji Reddy, the pharmaceutical industry pioneer who helped establish India’s reputation as a supplier of inexpensive medicines to the world...
- Blocking buyouts by MNCs misplaced nationalism: GV Prasad, Dr Reddy's LaboratoriesAny effort to put hurdles in the way of foreign drug firms buying Indian companies is 'misplaced nationalism,' GV Prasad, vice-chairman and...
- Dr Reddy's targeting five percentage points above market growth: GV PrasadDr Reddy's is targeting to grow at least five percentage points above the market growth and hopes to reach the goal over 18 months from now.
- Dr. Reddy's shares slip despite posting better Q1 resultsDr Reddy's Lab yesterday reported its quarterly results with a 20 pc uptick in profits however shares continued its southward journet today...
- Dr Reddy's eyes cos with branded generics presenceLeading drug maker Dr Reddy’s Laboratories will fashion its acquisition strategy around target companies that will give it a strong branded...
- Dr Reddy's developing 8 more biotech drugsDr. Reddy's Laboratories developing eight generic medicines using biotechnology.
Load More
